Alopecia areata (AA) is a common autoimmune disease that affects hair follicles and results in nonscarring hair loss. Pathophysiology remains actually unclear. However, genetics and immunity are confirmed as the most important contributors to disease. From the clinical point of view, AA is most often limited to a certain area in the form of alopecic plaques, but it can develop as a total loss of hair on the scalp (AA totalis) or it can even affect the entire body surface (AA universalis), causing a great psychosocial impact on the patient's life. 1 These extensive forms, with a worse prognosis, become frequently a real challenge for the dermatologist, as there are currently no fully effective therapeutic alternatives. 2,3 A 52-year-old woman with a personal history of hypothyroidism and Loeys-Dietz syndrome was attended at our Dermatology Department complaining a 2-year history of diffuse AA with ophiasis pattern. Complimentary test performed including blood cell count, general biochemistry, erythrocite sedimentation rate, C reactive protein, thyroid profile, and autoantibodies showed no anomalies. A psychological evaluation of the patient who ruled out anxiety-depressive syndrome was carried out. The dermatology life quality index (DLQI) scored 6. Treatment with minipulses of dexamethasone 6 mg twice weekly, methotrexate weekly, and topical minoxidil daily was then started. After 6 months of treatment, dexamethasone was suspended because of the appearance of cushingoid signs on examination, and methotrexate because of gastrointestinal intolerance. Other treatments with no satisfactory response included intralesional corticosteroids (triamcinolone of 40 mg/mL per 1 mL injection every month), topical immunomodulation